Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 13/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513200 | 0.84 | SOAT1 (1.00) | SOAT1RAB9AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6280133 | 0.84 | SOAT1 (0.81) | SOAT1RAB9AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL4513121 | 0.84 | SOAT1 (0.68) | SOAT1RAB9AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL4530498 | 0.83 | SOAT1 (0.67) | SOAT1RAB9AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6280341 | 0.83 | SOAT1 (1.00) | SOAT1 | |
| SCHEMBL6281841 | 0.82 | SOAT1 (0.78) | SOAT1RAB9AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6282104 | 0.82 | SOAT1 (1.00) | SOAT1 | |
| SCHEMBL6282018 | 0.82 | SOAT1 (0.87) | SOAT1 | |
| SCHEMBL6284669 | 0.82 | SOAT1 (0.76) | SOAT1 | |
| SCHEMBL4507782 | 0.82 | SOAT1 (0.65) | SOAT1RAB9AALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969711-B2 | Cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| EP-0987254-B1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | KOWA CO (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-0987254-A1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | LCAT, ACAT2, ACAT1 | SOAT1 5/4885RAB9A 4712/4885ALDH1A1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.